A Phase 2 Exploratory Study of Erlotinib and SNDX-275 in Participants With Non-small Cell Lung Carcinoma Who Are Progressing on Erlotinib
Trial details
- Registry ID
- NCT00750698
- Phase
- Phase 2
Drug identity checked against registry records
Also recorded as SNDX-275
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| A Phase 2 Exploratory Study of Erlotinib and SNDX-275 in Participants With Non-small Cell Lung Carcinoma Who Are Progressing on ErlotinibNCT00750698 | Syndax Pharmaceuticals | Phase 2 | Terminated | 2010-05Actual |
| No regulatory events match this view.This does not mean no FDA events have occurred. |